QTTB Company Profile and Key Details

NASDAQ : QTTB

Q32 Bio

$12.87

0.98+8.24%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Q32 Bio Inc. (QTTB) stock surged +8.24%, trading at $12.87 on NASDAQ, up from the previous close of $11.89. The stock opened at $11.87, fluctuating between $11.29 and $13.10 in the recent session.

Stock Snapshot

11.89

Prev. Close

164.43M

Market Cap

11.29

Day Low

4.63

P/E Ratio

2.78

EPS (TTM)

N/A

Cash Flow per Share

11.87

Open

12.78M

Number of Shares

13.1

Day High

36.58%

Free Float in %

N/A

Book Value

644.97K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 10, 2026	11.46	13.10	11.29	12.87	644.97K
Jun 09, 2026	12.19	12.55	11.59	11.89	628.05K
Jun 08, 2026	13.36	13.99	11.08	12.03	660.28K
Jun 05, 2026	13.80	14.49	12.84	13.11	764.82K
Jun 04, 2026	11.85	14.85	11.85	14.00	1.05M
Jun 03, 2026	12.52	13.10	11.53	12.19	535.05K
Jun 01, 2026	10.82	12.50	10.79	11.66	1.07M
May 29, 2026	10.64	12.15	10.35	11.05	1.2M
May 28, 2026	11.52	12.20	10.05	10.31	1.27M
May 27, 2026	9.17	13.15	9.15	12.85	21.07M
May 26, 2026	5.88	7.26	5.81	7.09	297.37K
May 22, 2026	5.75	6.14	5.61	5.80	623.67K
May 21, 2026	5.75	5.87	5.38	5.50	181.03K
May 20, 2026	6.02	6.07	5.60	5.67	283.54K
May 19, 2026	5.71	6.13	5.49	6.07	302.94K
May 18, 2026	6.30	6.59	5.69	5.75	245.1K
May 15, 2026	6.15	6.45	6.10	6.30	113.34K
May 14, 2026	6.02	6.28	5.66	6.25	157.37K
May 13, 2026	5.82	6.21	5.76	5.94	182.19K
May 12, 2026	5.18	5.90	5.08	5.81	644.53K

Contact Details

Waltham, MA 02451

United States

https://www.q32bio.com 781 999 0232

About Company

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human anti�interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Stock Peers

ARGX

-21.82-2.47%

argenx SE$862.18 REGN

-14.53-2.36%

Regeneron Pharmaceuticals, Inc.$601.65 UTHR

-9.04-1.63%

United Therapeutics Corporation$544.10 MDGL

-5.57-1.17%

Madrigal Pharmaceuticals, Inc.$471.32 VRTX

-10.06-2.26%

Vertex Pharmaceuticals Incorporated$435.71 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

2.66+0.86%

Krystal Biotech, Inc.$312.41 ALNY

-6.47-2.17%

Alnylam Pharmaceuticals, Inc.$291.22 LGND

4.96+2.04%

Ligand Pharmaceuticals Incorporated$248.24 AXSM

0.7+0.28%

Axsome Therapeutics, Inc.$246.34

Company Overview

Q32 Bio Inc. (NASDAQ:QTTB) closed at $12.87 USD, gaining $0.98 (8.24%) from the previous close of $11.89. The stock is currently mid-range between its 52-week high and low $1.34 and $14.85. With a market capitalization of about $164.43 million, Q32 Bio Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.23). Key stats such as the average daily volume over the past year has been around 744.18 thousand shares, in line with its 52-week average. Headquartered in Waltham, MA, Q32 Bio Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jodie Pope Morrison, the company employs approximately 28 people and listed since March 28, 2018. Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses.

Technical Performance

QTTB has shown sold momentum, gaining 7.97% over the past week and 23.97% over the past quarter, though year-to-date performance is up 18.37%. Short-term trend indicators are bearishly aligned (SMA20 14.16%, SMA50 27.24%, SMA200 86.11%). The stock’s 14-day RSI is 63.58 (firm momentum), while the ATR of 0.39 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -25.27% below its high and over 253.9% above its low. Average 10-day trading volume of 765.09 thousand shares is in line with the 3-month average of 766.42 thousand, indicating normal recent market interest.

Valuation Metrics

Q32 Bio Inc. trades at a P/E ratio of 5.0, slightly below the S&P 500 average, with a price-to-sales ratio of 2.8 and a price-to-book ratio of 3.59 trading at moderately above to book value. The P/FCF stands at -5.49, also below market averages.

Dividend & Fair Value

Q32 Bio Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.26. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Q32 Bio Inc. generated EPS of -$3.45 over the past year. Five-year average earnings growth is 31.75%. Wall Street analysts project EPS growth of 15.19% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $13.00. The high target offers 8.78% upside. The low target suggests 1.01% downside. The mean target is $13.33. This offers 3.57% upside. Q32 Bio Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 05, 2026, missed forecasts by -20.59%. The prior quarter beat by -529.41%. Over the last six quarters, Apple has recorded several small beats. These include -7.2% in March 11, 2025.

Shareholding & Insider Activity

Q32 Bio Inc. has 12.20 million shares outstanding. The public float is 5.39 million shares, elevated short interest at 8.94% of float. This equals 306.89 thousand shares. The short ratio is 2.0 days. Institutional investors hold 70.3% of the float. Insiders own 6.52%. Xu Diyong holds 625.00 thousand shares, ORBIMED ADVISORS LLC has 625.00 thousand shares and Morrison Jodie Pope has 89.10 thousand shares. Over the past six months, insider transactions show net selling. They sold 16.71 thousand shares across 3 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Q32 Bio has not generated any revenue.
On valuation metrics, Q32 Bio trades at a P/E of 5.00, P/S of 2.80 and P/B of 3.59. The current ratio is 5.36 and quick ratio is 5.36. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -879.50 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.24, supported by a cash flow-to-debt ratio of -2.49.

Price Forecast & Outlook

Our AI price prediction model suggests that Q32 Bio Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 15.54%, with price expected at $14.87 by June 24, 2026, within a range of $12.75 to $17.05 3-Month Outlook: Projected fall of -77.39%, reaching $2.91 by September 08, 2026, with a range of $1.83 to $3.27. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by June 10, 2027, within a range of $0.00 to $1.02.

Key Takeaways

Q32 Bio Inc. (NASDAQ:QTTB) shares are up 18.37% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Q32 Bio Inc. trading at a premium to the broader market with a P/E of 5.0. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $23.93, suggesting 85.94% upside. Our AI forecast model points to short-term strength (15.54% over two weeks), a medium-term fall (-77.39% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Q32 Bio Inc. (QTTB) stock price?

Q32 Bio Inc. (NASDAQ: QTTB) stock price is $12.87 in the last trading session. During the trading session, QTTB stock reached the peak price of $13.10 while $11.29 was the lowest point it dropped to. The percentage change in QTTB stock occurred in the recent session was 8.24% while the dollar amount for the price change in QTTB stock was $0.98.

QTTB's industry and sector of operation?

The NASDAQ listed QTTB is part of Biotechnology industry that operates in the broader Healthcare sector. Q32 Bio Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of QTTB?

No Data

How QTTB did perform over past 52-week?

QTTB's closing price is 856.88% higher than its 52-week low of $1.35 where as its distance from 52-week high of $14.85 is -13.33%.

How many employees does QTTB have?

Number of QTTB employees currently stands at 28.

Link for QTTB official website?

Official Website of QTTB is: https://www.q32bio.com

How do I contact QTTB?

QTTB could be contacted at phone 781 999 0232 and can also be accessed through its website. QTTB operates from 830 Winter Street, Waltham, MA 02451, United States.

How many shares of QTTB are traded daily?

QTTB stock volume for the day was 644.97K shares. The average number of QTTB shares traded daily for last 3 months was 744.19K.

What is the market cap of QTTB currently?

The market value of QTTB currently stands at $164.43M with its latest stock price at $12.87 and 12.78M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	28
Beta	-0.12
Sales or Revenue	N/A
5Y Sales Change%	-1.166%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

QTTB Company Profile and Key Details

Q32 Bio

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook